BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17947643)

  • 1. Calcineurin inhibitors block MHC-restricted antigen presentation in vivo.
    Lee YH; Lee YR; Im SA; Park SI; Kim KH; Gerelchuluun T; Song S; Kim K; Lee CK
    J Immunol; 2007 Nov; 179(9):5711-6. PubMed ID: 17947643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells.
    Lee YR; Yang IH; Lee YH; Im SA; Song S; Li H; Han K; Kim K; Eo SK; Lee CK
    Blood; 2005 May; 105(10):3951-5. PubMed ID: 15657176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baccatin III, a synthetic precursor of taxol, enhances MHC-restricted antigen presentation in dendritic cells.
    Lee YH; Lee YR; Kim KH; Im SA; Song S; Lee MK; Kim Y; Hong JT; Kim K; Lee CK
    Int Immunopharmacol; 2011 Aug; 11(8):985-91. PubMed ID: 21354357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells.
    Mitchell DA; Nair SK; Gilboa E
    Eur J Immunol; 1998 Jun; 28(6):1923-33. PubMed ID: 9645374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen.
    Lee YR; Lee YH; Im SA; Yang IH; Ahn GW; Kim K; Lee CK
    Arch Pharm Res; 2010 Nov; 33(11):1859-66. PubMed ID: 21116790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
    Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance.
    Bonifaz L; Bonnyay D; Mahnke K; Rivera M; Nussenzweig MC; Steinman RM
    J Exp Med; 2002 Dec; 196(12):1627-38. PubMed ID: 12486105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR7 triggering with polyuridylic acid promotes cross-presentation in CD8α+ conventional dendritic cells by enhancing antigen preservation and MHC class I antigen permanence on the dendritic cell surface.
    Crespo MI; Zacca ER; Núñez NG; Ranocchia RP; Maccioni M; Maletto BA; Pistoresi-Palencia MC; Morón G
    J Immunol; 2013 Feb; 190(3):948-60. PubMed ID: 23284054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
    Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
    Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes.
    Cruz-Leal Y; Grubaugh D; Nogueira CV; Lopetegui-González I; Del Valle A; Escalona F; Laborde RJ; Alvarez C; Fernández LE; Starnbach MN; Higgins DE; Lanio ME
    Front Immunol; 2018; 9():2473. PubMed ID: 30455685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells.
    Tardif V; Riquelme SA; Remy S; Carreño LJ; Cortés CM; Simon T; Hill M; Louvet C; Riedel CA; Blancou P; Bach JM; Chauveau C; Bueno SM; Anegon I; Kalergis AM
    Eur J Immunol; 2013 Nov; 43(11):2832-44. PubMed ID: 23852701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes.
    Porgador A; Gilboa E
    J Exp Med; 1995 Jul; 182(1):255-60. PubMed ID: 7540653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
    Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
    J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
    Maecker HT; Umetsu DT; DeKruyff RH; Levy S
    J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MHC class I-restricted presentation of maleylated protein binding to scavenger receptors.
    Bansal P; Mukherjee P; Basu SK; George A; Bal V; Rath S
    J Immunol; 1999 Apr; 162(8):4430-7. PubMed ID: 10201979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Archaeosomes induce long-term CD8+ cytotoxic T cell response to entrapped soluble protein by the exogenous cytosolic pathway, in the absence of CD4+ T cell help.
    Krishnan L; Sad S; Patel GB; Sprott GD
    J Immunol; 2000 Nov; 165(9):5177-85. PubMed ID: 11046050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
    Rock KL; Clark K
    J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis.
    Reis e Sousa C; Germain RN
    J Exp Med; 1995 Sep; 182(3):841-51. PubMed ID: 7650490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.